PeerVoice Brain & Behaviour Video

PeerVoice
  • 0.0 (0)
  • SCIENCE
  • MONTHLY
PeerVoice Brain & Behaviour Video Podcast

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  1. 22 AUG

    Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML

    Visit https://www.peervoice.com/EHB860 to view the entire programme with slides. After completing “Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML”, participants will be able to: Recognize the disease- and treatment-related health burdens faced by patients with acute myeloid leukemia; and Apply best practices in patient communication in order to empower people with AML to become active partners in care.

    27 min

  2. 22 JUL

    Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making

    Visit https://www.peervoice.com/KHV860 to view the entire programme with slides. After completing “Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making”, participants will be able to: Identify best practices to optimize the recognition and diagnosis of patients with transthyretin amyloidosis (ATTR), including those with ATTRv-PN and those with mixed phenotype ATTR; Evaluate current and emerging treatment options for hereditary ATTR with polyneuropathy (ATTRv-PN), including key differences between therapies with regards to clinical trial design, patient populations studied, available outcomes, and administration considerations; and Apply a comprehensive, patient-centered approach to management of patients with ATTR, including those with ATTRv-PN and those with mixed phenotype ATTR.

    53 min

  3. 10 JUL

    Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis

    Visit https://www.peervoice.com/JAQ860 to view the entire programme with slides. After completing “Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis”, participants will be able to: Summarise the latest clinical data on emerging FcRn inhibitors in generalised myasthenia gravis (gMG); and Evaluate how emerging evidence is advancing identification of the need for, and optimised management with, FcRn inhibitors in patients with gMG.

    20 min

  4. 3 JUL

    Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia

    Visit https://www.peervoice.com/DRF860 to view the entire programme with slides. After completing “Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia”, participants will be able to: Recognize health risks associated with idiopathic hypersomnia; Differentiate idiopathic hypersomnia from other conditions that cause excessive daytime sleepiness (EDS); Explain how to establish a confirmatory diagnosis of idiopathic hypersomnia; and Propose effective, individualized, evidence-based management strategies for patients with idiopathic hypersomnia.

    1h 29m

  5. 3 JUL

    Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy

    Visit https://www.peervoice.com/RHA860 to view the entire programme with slides. After completing “Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy”, participants will be able to: Describe the pathophysiology of narcolepsy in the context of cardiovascular (CV) effects; Differentiate between narcolepsy medications regarding their impact on CV risk factors; Identify medications used for common comorbidities associated with narcolepsy that have the potential to increase CV risk; and Propose strategies to manage CV risk in patients with narcolepsy.

    1h 2m

  6. 30 MAY

    Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?

    Visit https://www.peervoice.com/BBT860 to view the entire programme with slides. After completing “Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?”, participants will be able to: Describe the benefits and limitations of current disease-modifying strategies in multiple sclerosis (MS); Discuss the role of Bruton’s tyrosine kinase (BTK) in the pathological processes associated with disease progression in patients with MS; and Use clinical data to evaluate on-target and off-target effects of emerging BTK inhibitors for patients with MS in the context of current clinical management.

    20 min

  7. 26 MAR

    Ali Aamer Habib, MD - Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies for Generalised Myasthenia Gravis

    Visit https://www.peervoice.com/JEG860 to view the entire programme with slides. After completing “Ali Aamer Habib, MD - Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies for Generalised Myasthenia Gravis”, participants will be able to: Describe the limitations of current targeted immunotherapies for patients with generalised myasthenia gravis (gMG); Identify emerging targeted therapies for gMG; and Explain how emerging targeted therapies for gMG differentiate from other therapies within the same class.

    25 min

  8. 5 MAR

    Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

    Visit https://www.peervoice.com/PBV860 to view the entire programme with slides. After completing “Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis”, participants will be able to: Describe the role of autoantibodies in the pathophysiology of generalised myasthenia gravis (gMG); Identify the specific autoantibodies associated with gMG and the effects they have on the neuromuscular junction (NMJ); Explain why identifying autoantibody specificity is important for optimising clinical outcomes in patients with gMG; and Use the serological autoantibody status of patients with gMG to determine which therapeutic class is most appropriate for optimising clinical outcomes.

    22 min
See All (34)

About

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Information

More From PeerVoice

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada